All In MedTech

Device Trial Radar · NCT06788977

External Trigeminal Nerve Stimulation for Migraine Treatment in Pregnancy

CEFALY Pregnancy Registry

Last checked: Nov 19, 2026Latest source record: Apr 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

550

Planned (sponsor's estimate)

Start

Nov 25, 2024

Primary completion

Apr 2027

Study completion Dec 2030

Sponsor

Lead sponsor
Cefaly TechnologyNot on our public-company list
Sponsor type
Industry
First posted
Jan 23, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
Female only, from 18 years, up to 44 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This online registry aims to understand the potential benefits and safety of external trigeminal nerve stimulation for the treatment of migraine in pregnant women. Women do not need to use external trigeminal nerve stimulation or any other form of migraine treatment to participate in the registry. The main question it aims to answer is: Is external trigeminal nerve stimulation a safe and effective option for migraine treatment during and after pregnancy? There are no required changes in migraine treatment to participate in this registry. Participants may or may not use external trigeminal nerve stimulation or any other treatment they currently use and may still participate in the registry. There are no clinic or research visits, as the registry is entirely online. Participants will be asked to complete up to six 15- 20-minute surveys over a time period of up to 12 months.

Conditions

  • Pregnancy
  • Migraine
  • Headache
  • Postpartum
  • Depression
  • Anxiety

Interventions

  • external Trigeminal Nerve StimulationDevice

    External trigeminal nerve stimulation (e-TNS) is a non-invasive, nondrug option for the acute and preventative treatment of migraine. The device is marketed under the trade name CEFALY and has received clearance from the US Food and Drug Administration (FDA) for the acute and preventative treatment of migraine. The CEFALY device provides transcutaneous stimulation of the supraorbital and supratrochlear branches of the ophthalmic division of the Trigeminal nerve. Patients apply a self-adhesive electrode pad to their forehead, then place the CEFALY generator over the electrodes, resulting in a magnetic connection. The user then selects a treatment program for acute or preventative therapy, which lasts for 60 or 20 minutes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of miscarriage per trimesterTime frame: through study completion average 2 years
  2. Postpartum Bonding according to the Maternal-to-Infant Bonding ScaleTime frame: through study completion average 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • https://public.smart-trial.co/#/public/649d77f0e8f8d0fb993d0c61/6626f6a04f0a3c7dd0860e14/662726d84f0a3c7dd08aeaa0/signup?lang=en-us&enforceLanguage=true

    Darien, Connecticut · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.